Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study

• DOI: 10.1016/j.clml.2022.09.007
• Publication Date: 2022-10-07T03:40:04Z
• Authors: Anthony R. Mato; Lisa M. Hess; Yongmei Chen; Paolo B. Abada; Heiko Konig; John M. Pagel; Richard A. Walgren
• Keywords: Discontinuation

This study describes the treatment patterns and outcomes of patients with CLL/SLL in a de-identified real-world oncology electronic health records database.Adult were eligible if they had received cBTKi therapy, both BCL2i, or all 4 drug classes (cBTKi, rituximab, chemotherapy) at any time during first 5 lines therapy. Time-to-event evaluated using Kaplan Meier method. No statistical comparisons conducted; analyses descriptive conducted SAS Enterprise.A total 9578 eligible: 52.0% (n = 4983) least one cBTKi, 6.1% 581) 2.3% 218) four therapies chemotherapy). Of those who discontinued these treatments, only 39.5% 1 206/3 577), 59.7% 228/382), 55.0% 82/149) subsequent therapy (post-cBTKi, post-cBTKi/post-BCL2i, post-all therapies, respectively). Median from discontinuation to death was 9.5 months (all cBTKi) 5.6 (those BCL2i) 3.9 (patients therapies). The median duration next among additional post-cBTKi 4.1 months; post-cBTKi/post-BCL2i 5.5 immediate after 5.1 months.The poor observed across cohorts this demonstrate need for effective treatments that can improve CLL/SLL.